XmAb13676
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Non-Hodgkins Lymphoma
Conditions
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Trial Timeline
Oct 1, 2016 → Apr 1, 2024
NCT ID
NCT02924402About XmAb13676
XmAb13676 is a phase 1 stage product being developed by Xencor for B-cell Non-Hodgkins Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02924402. Target conditions include B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07284797 | Phase 1 | Recruiting |
| NCT07230353 | Phase 1 | Recruiting |
| NCT02924402 | Phase 1 | Completed |
Competing Products
20 competing products in B-cell Non-Hodgkins Lymphoma